{"id":"W4292103594","doi":"10.1136/jitc-2022-004761","title":"Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Hôtel-Dieu de Québec","funders":"Foundation Medicine; National Center for Advancing Translational Sciences; Ono Pharmaceutical; Clovis Oncology; Bristol-Myers Squibb","keywords":"Medicine; Enzalutamide; Prostate cancer; Nivolumab; Internal medicine; Oncology; Cohort; Progression-free survival; Cancer; Urology; Chemotherapy; Androgen receptor; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001904739,0.0009273898,0.00114918,0.0002294327,0.0002645,0.001087513,0.0006077807,0.0008385953,0.003740575],"category_scores_gemma":[0.001623122,0.0002297204,0.001344173,0.0002776077,0.0003203599,0.0005871108,0.000321122,0.00157163,0.0005214384],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000816742,"about_ca_system_score_gemma":0.001012437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001006881,"about_ca_topic_score_gemma":0.003306231,"domain_scores_codex":[0.999403,0.0003460475,0.00002727207,0.0000853952,0.00006324868,0.00007503635],"domain_scores_gemma":[0.9992853,0.0001736339,0.0001716241,0.00006452164,0.00006211866,0.0002428609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8081954,0.01144462,0.009462855,0.003250397,0.005661745,0.0001529731,0.0001433691,0.002933769,0.007773282,0.0005476346,0.01955865,0.1308753],"study_design_scores_gemma":[0.8748626,0.07688961,0.02630038,0.0003614413,0.00354635,0.0003571824,0.00007946266,0.001844723,0.001555741,0.0008543285,0.01328747,0.00006075978],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9455501,0.03416805,0.0006380597,0.002123709,0.0006083005,0.002641062,0.006979989,0.0001609942,0.007129654],"genre_scores_gemma":[0.973446,0.007594077,0.001127554,0.002358925,0.0005510839,0.002272861,0.009716159,0.00004427672,0.002889088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003740575,"threshold_uncertainty_score":0.01251346,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07347743674206077,"score_gpt":0.4234544933584976,"score_spread":0.3499770566164369,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}